08 Aug management Posted at 09:36h in by adminaltheia 0 Comments 0 Likes PAOLO FIORINA, MD PhDCO-FOUNDER & CHIEF SCIENTIFIC OFFICERPAOLO FIORINA, MD PhDCO-FOUNDER & CHIEF SCIENTIFIC OFFICERPaolo Fiorina, MD, PhD is an endocrinologist. He is Director, International Center for T1D, Romeo ed Enrica Invernizzi Pediatric, University of Milan, Italy; Professor of Endocrinology, L. Sacco Hospital, University of Milan; Chief of Division of Endocrinology, ASST Sacco-Fatebenefratelli, Milan, Italy and Lecturer on Pediatrics, Boston Children’s Hospital, Harvard Medical School. He is actively involved in the Grant Committee of JDRF, Medical Science Review Committee (MSRC) for Islet Biology and Transplantation, Transplant Meeting Committee at the San Raffaele Hospital (Milan), American Heart Association (AHA), and American Society of Transplantation (AST).He published over 140 peer-reviewed manuscripts (5700+ citations, h-index 44). He is focused in devising new immune-based preventive and therapeutic strategies for autoimmune diseases.His publication track record includes seminal contribution to the field of immunotherapy for the treatment of type 1 diabetes and of transplantation and stem cells to prevent and treat autoimmune diabetes and allograft rejection.PAOLO RIZZARDI, MDCO-FOUNDER, CHAIRMAN OF THE BOARD & CEOPAOLO RIZZARDI, MDCO-FOUNDER, CHAIRMAN OF THE BOARD & CEOPaolo Rizzardi, MD, internist, is co-Founder, Chairman&CEO of Altheia Science, a clinical-ready SME developing innovative gene therapy approaches in autoimmunity and cancer. He combines a strong scientific background with managerial skills gained in substantially contributing to successfully develop biotechnology companies and to achieve the market approval of advanced therapy medicinal products in the cell&gene therapy and oncology field. After spending more than 10 years in academia in Italy, UK, and Switzerland in developing programs for innovative immune-based/vaccination strategies in patients with HIV/AIDS, he has worked for more than 20 years in the cell&gene therapy biotech sector, developing a unique expertise in R&D, CMC, clinical and business development, development, engineering, and IP from target validation to market approval. He is co-Founder of AurorA-TT, a technology transfer initiative focused in the biotech sector.He published over 90 peer-reviewed manuscripts and textbook chapters (6000+ citations, h-index 36), including seminal contribution to the field of gene therapy and HIV infection.ALESSANDRA BIFFI, MDCO-FOUNDER, BOARD MEMBER & CHIEF SCIENTIFIC OFFICERALESSANDRA BIFFI, MDCO-FOUNDER, BOARD MEMBER & CHIEF SCIENTIFIC OFFICERAlessandra Biffi, MD, is a pediatric hematologist and stem cell transplant physician. She is Professor of Pediatrics, University of Padua and Chief of the Pediatric Onco-hematology Unit of Padua Hospital; until September 2018, Director of the Gene Therapy Program, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Principal Scientist at the Harvard Stem Cell Institute, Chair of the Scientific Review Committee for Gene Therapy at Boston Children’s Hospital, and Associate Professor of Pediatrics Harvard Medical School.She published over 60 peer-reviewed manuscripts and textbook chapters. She is actively involved in gene therapy trials for neurological genetic diseases, hemoglobinopathies and immunodeficiencies and has developed a unique expertise in the pre-clinical development and clinical testing of hematopoietic stem cell gene therapy approaches.Her publication track record includes seminal contribution to the field of cell and gene therapy.ANNITA MONTEPELOSO, PHDRESEARCHER OFFICERANNITA MONTEPELOSO, PHDRESEARCHER OFFICERAnnita Montepeloso, PhD, is a senior researcher with over 10 years of experience in the field of hematopoietic stem and progenitor cell (HSPC) gene therapy for neurodegenerative and neurometabolic diseases. She developed her carrier working at the San Raffaele Telethon Institute for Gene Therapy in Milano between 2013 and 2015, and from 2015 to 2022 at the Gene Therapy Program, Dana Farber/Boston Children’s Hospital, Harvard Medical School in Boston, MA.Her research contributed to the development of innovative strategies for the treatment of neurodegenerative and neurometabolic diseases and in the development of preclinical and clinical protocol for advanced gene therapy applications based on HSPC.Her work is published in peer-reviewed journals in the field of cell and gene therapy.RITA MILAZZO, PhDRESEARCHER DIRECTORRITA MILAZZO, PhDRESEARCHER DIRECTORRita Milazzo, PhD, is a senior researcher with over 15 years of experience in the field of hematopoietic stem and progenitor cell (HSPC) gene therapy for neurodegenerative and autoimmune diseases.She developed her carrier working at the San Raffaele Telethon Institute for Gene Therapy in Milano, where she focused on the identification of critical factors enhancing HSPC-based transplant procedures for diseases with severe nervous system involvement.Her research contributed to the development of innovative strategies for the treatment of neurological genetic diseases and in the translation of pre-clinical data into the design of human clinical trials, as in the case of metachromatic leukodystrophy.Her work is published in peer-reviewed journals in the field of cell and gene therapy.MARTINA PIGAZZI, PhDSCIENTIFIC ADVISORMARTINA PIGAZZI, PhDSCIENTIFIC ADVISORMartina Pigazzi, PhD, is Associate Professor at Woman and Child health Department, Onco-Hematology Clinic and Lab at the University of Padova. From 2008 she is the geneticist responsible for the diagnosis of all hematological disorders at her institute, and she is in charge of the molecular diagnostics for all Italian patients affected with acute myeloid leukemia and enrolled in trials of the Associazione Italiana Emato-Oncologia Pediatrica (AIEOP). She is a member of the AIEOP LAnL Group, delegate at the International BFM Study Group for the international committee "I-BFM MRD-AML Task Force" and the Coordinator of the Genetics AML Molecular Group-BFM. Main research interest is the identification of new tumour-specific antigens that may serve as restricted targets for targeted therapies and of new genetic aberrations and mutations with prognostic value to be used as biomarker to improve diagnosis and patient’s risk stratification.She is author of more than 50 manuscripts published in peer-reviewed journals.MOUFIDA BEN NASR, PhDRESEARCHER DEVELOPERMOUFIDA BEN NASR, PhDRESEARCHER DEVELOPERMoufida Ben Nasr M, PhD, is an immunologist. She is Research Fellow at Nephrology Division, Boston Children’s Hospital, Harvard Medical School.She published over 20 peer-reviewed manuscripts. She is focused in immunology and stem cell biology to develop strategies for transplantation and the treatment of hematological malignancies and autoimmune diseases.Her publication track record includes important contribution to the field of immunobiology and immunotherapy of type 1 diabetes, identifying mechanisms to be targeted to prevent the attack of autoreactive T cells.PIERLUIGI PARACCHI, MEcCO-FOUNDER, BOARD MEMBER & STRATEGY CONSULTANTPIERLUIGI PARACCHI, MEcCO-FOUNDER, BOARD MEMBER & STRATEGY CONSULTANTPierluigi Paracchi, MEc, is co-Founder and Venture Consultant of AurorA-TT, a technology transfer initiative fully focused in the biotech sector, and co-Founder, board member and Strategy Consultant of Altheia Science.He has more than 15 years of experience as venture capitalist and biotech entrepreneur. He was Founder & CEO of Quantica, the first Italian VC firm exclusively dedicated to research and academic spin-out companies and Venture Consultant at Sofinnova Partners. He was investors and Board Member at EOS – Ethical Oncology Science, acquired by Clovis Oncology for 470M.He is Co-Founder and CEO of Genenta Science, a cancer gene therapy spin-out from San Raffaele Hospital, the first Italian company listed at NASDAQ in 2021 (NASDAQ: GNTA). He is Board Member at Assobiotec and Chairman of the SMEs group.